HepaTx is a pioneering brand that is revolutionizing the treatment of liver disease with their groundbreaking stem cell-based therapy, providing an alternative to transplantation. Their technology enables liver regeneration through hepatocyte infusion, offering numerous benefits for patients, physicians, and investors. One of HepaTx's key strengths is its optimal go-to-market strategy, which is faster and more efficient than traditional development pathways.

This is achieved through their scalable, fully-defined manufacturing process and innovative regulatory approach, allowing them to reach critical milestones efficiently. HepaTx holds an exclusive worldwide license from Stanford, covering critical technology. They are actively building an extensive intellectual property portfolio that includes additional manufacturing technologies and therapeutic applications.

Unlike hepatocytes obtained from cadavers or liver donors, HepaTx has an unlimited supply of their allogeneic cell therapy product, ensuring on-demand availability. With an experienced and talented team supported by industry and academic advisors, HepaTx is well-equipped to execute their plan successfully. Their pipeline includes niche indications with lower developmental costs, rapid regulatory approval paths, and large market chronic liver disease indications such as Alpha 1 anti-trypsin deficiency (A1ATD), Phenylketonuria (PKU), and Non-alcoholic steatohepatitis (NASH).

Recognized as the 2022 Impact Company of The Year by DotCom Magazine, HepaTx is dedicated to making a significant impact in the field of liver disease treatment. If you are interested in investment or career opportunities with HepaTx, they would be delighted to hear from you